Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study.
MAY 19, 2022 | BUSINESS WIRE
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study. Eritoran, an investigational TLR-4 antagonist discovered and developed by Eisai, was selected for evaluation because it was hypothesized to suppress the over-production and release of various pro-inflammatory mediators (“cytokine storm”) observed in some COVID-19 patients by modulating the production of inflammatory cytokines. The decision to terminate the evaluation was due to changes in the COVID-19 landscape.
REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (known as the REMAP-COVID sub-study in the U.S.), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. The international trial uses an innovative trial design to efficiently evaluate multiple interventions simultaneously with treatments tested within groupings or “domains” based on pathway or mechanism of action.
To date, REMAP-CAP includes 55 current or completed interventions in 16 domains. Research from REMAP-CAP has supported numerous treatment guidelines for patients hospitalized with COVID-19 and has contributed to over 15 publications including NEJM and JAMA.
About Global Coalition for Adaptive Research (GCAR)
The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) nonprofit organization uniting physicians, clinical researchers, advocacy and philanthropic organizations, biopharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases by serving as Sponsor of innovative and complex trials including master protocols and platform trials. GCAR is the U.S. Trial Sponsor of REMAP-CAP.
To learn more about GCAR, visit www.gcaresearch.org
REMAP-CAP is led by world experts in critical care, clinical trials, pandemic and infectious disease outbreaks, virology, immunology, emergency medicine, and Bayesian statistics. REMAP-CAP has enrolled over 19,900 patients at 361 sites across 21 countries. This vital research is being conducted in collaboration with Berry Consultants, leaders in statistical design for adaptive platform trials, and is being supported by governments and non-profits worldwide.
To learn more about REMAP-CAP and the REMAP-COVID sub-study, please visit www.remapcap.org and follow @remap_cap